Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
115 studies found for:    MAST CELL DISEASE
Show Display Options
RSS Create an RSS feed from your search for:
MAST CELL DISEASE
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
2 Recruiting Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis (ASM);   Systemic Mastocytosis With Associated Clonal Hematological Non-mast Cell Lineage Disease (SM-AHNMD);   Mast Cell Leukemia (MCL);   Smoldering Systemic Mastocytosis (SSM);   Indolent Systemic Mastocytosis (ISM) [ISM Subgroup Fully Recruited]
Intervention: Other: Interview
3 Active, not recruiting Treatment of Indolent Systemic Mastocytosis With PA101
Conditions: Mastocytosis;   Systemic Mastocytosis;   Indolent Systemic Mastocytosis
Interventions: Drug: PA101;   Drug: Placebo
4 Recruiting Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Conditions: Aggressive Systemic Mastocytosis;   Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease;   Mast Cell Leukemia;   Relapsed or Refractory Myeloid Malignancies
Intervention: Drug: BLU-285
5 Recruiting Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis;   Associated Clonal Hematological Non-Mast-Cell Lineage Disease
Interventions: Drug: Ibrutinib;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
6 Completed Imatinib in KIT-negative Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Imatinib Mesylate
7 Recruiting Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
8 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin
9 Unknown  Molecular Mechanisms and Diagnosis of Mastocytosis
Condition: Mastocytosis
Intervention:
10 Recruiting Mast Cell Connect: A Registry for Patients With Mastocytosis
Condition: Mastocytosis
Intervention:
11 Terminated
Has Results
Obatoclax for Systemic Mastocytosis
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Obatoclax Mesylate
12 Completed Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
Conditions: Atopic Dermatitis;   Healthy;   Mastocytosis
Intervention:
13 Completed Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Condition: Cutaneous Mastocytosis
Intervention: Drug: TF 002
14 Completed Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Ontak (Denileukin Diftitox)
15 Completed
Has Results
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: RAD001 (Everolimus)
16 Recruiting Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Procedure: Mastocytosis diagnosis
17 Completed Cause and Natural Course of Pediatric-Onset Mastocytosis
Condition: Mastocytosis
Intervention:
18 Active, not recruiting Midostaurin in Indolent Systemic Mastocytosis
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: Midostaurin,
19 Completed Characteristics of Mast Cells in Mastocytosis
Condition: Mastocytosis
Intervention:
20 Completed Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Conditions: Mastocytosis;   Anaphylaxis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years